- Home
Welcome !
We hope you enjoy your visit on the website of CHU Brugmann (Brugmann University Hospital), a member of the IRIS network and of the CHU of Brussels.
With its three complementary sites and 853 recognized beds, CHU Brugmann is one of the largest hospitals in Brussels. Its assets ? An ideal size to deploy all its activities and the best possible service, a strong social personality and a resolutely university character. Without counting an advanced technical environment and constant architectural improvements. Besides, CHU Brugmann remains one of the rare hospitals with pavilion structure in Europe.
- Virtual hospital
Three complementary sites
Quality labels
As a member of the Brussels public hospitals network IRIS, CHU Brugmann adheres to the patients' charter. It is certainly an additional guarantee to be well received...
Networks
- Departments
- Consultations
Appointments
If you can not come to your appointment, please let us know at least 24 hours in advance via Internet or via our free phone line : 0800/35.088.
- Hospitalization
- Education
- Research
The Brugmann Foundation is a non-profit organization created within the CHU Brugmann and mandated to develop and support scientific research and stimulate the development of new medical treatments...
- Last news
Guided tour of CHU Brugmann
Addresses, means of access and plans
Brugmann in numbers
Organization and flowcharts
Who's who ?
Contact us
Administrative and tech departments
Medical clinics and departments
Multidisciplinary departments
Nursing and paramedical department
Paramedical departments
Statuary and legal organs
Consultants and consultation hours
Online appointment request
Online appointment cancellation
Online information brochures
A foundation for research
List of ongoing clinical trials
Press releases
News headlines
Job vacancies
Description of the research protocol "NeoRHEA"
Neoadjuvant Biomarker Research Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast Cancer
Phase II study| Status : Ongoing and recruiting
Additional details
Indication (or studied pathology) : Cancer du sein Néo-adjuvant
Brugmann identifier : NeoRHEA
EudraCT identifier :
2016-000879-24
Resources
Involved department : Hemato-oncology
Principal investigator : Besse/Efira
Sponsor : IJB
Contact : Clinical Research Unit
This protocol was approved by the Bordet ethics committee.
chu brugmann•Head office : Place A. Van Gehuchten 4 - 1020 Brussels
Page updated on 02/04/2019 (based on CRU data)